A5027104347- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Obstructive Sleep Apnea Research
- Inhalation and Respiratory Drug Delivery
- IL-33, ST2, and ILC Pathways
- Venous Thromboembolism Diagnosis and Management
- Immune Response and Inflammation
- Eosinophilic Esophagitis
- Eosinophilic Disorders and Syndromes
- Vasculitis and related conditions
- Bariatric Surgery and Outcomes
- Urticaria and Related Conditions
- Injury Epidemiology and Prevention
- Pharmaceutical studies and practices
- Cystic Fibrosis Research Advances
- Occupational exposure and asthma
- Sinusitis and nasal conditions
- Body Composition Measurement Techniques
- Cancer and Skin Lesions
- Burn Injury Management and Outcomes
- Health and Lifestyle Studies
- Tracheal and airway disorders
- Heart Rate Variability and Autonomic Control
- COVID-19 Clinical Research Studies
Hospital Universitario La Paz
2012-2024
Hospital La Paz Institute for Health Research
2015-2023
Instituto de Salud Carlos III
2023
Universidad Autónoma de Madrid
2021-2023
Centro de Investigación Biomédica en Red
2021-2023
GlaxoSmithKline (Spain)
2021
Thomas Foundation
2020
Cleveland Clinic Florida
2020
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2016
Hôpital Jeanne de Flandre
2010-2012
The efficacy of mepolizumab is well documented in severe eosinophilic asthma (SEA), although the stringent selection criteria adopted by SEA clinical trials limits generalizability results. Our study evaluated effectiveness and safety patients with Spain. primary endpoint was change rate clinically significant exacerbations 12 months after starting compared to baseline prior treatment. Patients were stratified blood eosinophil counts. We conducted a multicentric observational cohort treated...
Identifying inflammatory phenotypes is relevant in severe uncontrolled asthma. The aim of this study was to identify the different clinical, inflammatory, functional, and molecular patients with asthma investigate potential role sputum periostin as a biomarker phenotypes.Sputum induction performed 62 diagnosed Skin prick testing, lung function tests, exhaled nitric oxide, hematimetry, total serum IgE were performed. Periostin measured supernatants.Patients phenotyped 80% had late-onset...
Obstructive sleep apnoea is a risk factor for pulmonary embolism. Elevated D-dimer levels and other biomarkers are associated with recurrent The objectives were to compare the frequency of elevated (>500 ng·mL −1 ) further coagulation after oral anticoagulation withdrawal in embolism patients, without obstructive apnoea, including two control groups We performed home respiratory polygraphy. also measured basic biochemical profile haemogram, (D-dimer, prothrombin fragment 1+2,...
Abstract Background Severe asthma affects a small population but carries high psychopathological risk. Therefore, the psychodemographic profile of these patients is interest. A substantial prevalence anxiety, depression, alexithymia and hyperventilation syndrome in severe known, contradictory results have been observed. These factors can also affect patients’ quality life. For this reasons, our purpose to evaluate with assess their impact on life asthma. Methods cross-sectional study 63...
To assess the safety of biological therapy for severe T2 asthma (omalizumab, mepolizumab, benralizumab and reslizumab) under real-life conditions in elderly patients older than 70 years.Retrospective data collection including clinical characteristics, comorbidities, treatment, disease control adverse events (AE) all with on years seen Severe Asthma Unit our hospital.Of 147 being treated biologics, 21 were included. The median age these was 76.3 (range 71-86) majority women (n = 18, 85.7%)....
pressure of oxygen, mm Hg; Paw airway pressure, cm H2O/L/sec; PCT procalcitonine, ng/ml; Pplat plateau H2O; Raw resistance, TV tidal volume, ml/kg IBW (ideal body weight).ECMO was on day 4 and 14.Day 12, administration first dose reslizumab.Day 16, start empirical treatment with broad-spectrum antibiotherapy.No microorganisms were isolated at any time in microbiological samples (BAS, BAL, blood, urine.